
Massachusetts Biotech Boom Delivers VC Cash, But Workforce Shrinks
Massachusetts’ biotech scene shows a mixed picture: venture capital funding in H1 2026 totaled $3.45B (up 25% YoY) with Cambridge and Boston leading deals and eight IPOs signaling a strong exit environment, while NIH funding remains a bright spot per capita (Massachusetts at 9.3% of NIH funding and $477 per person) even as total NIH awards fell 6.2%. Early-stage financing looks mixed: seed rounds rose (15→21) but average raises dropped from $7.6M to $4.6M. Biopharma R&D jobs fell about 3,600 in 2025 (3.1%), though there was a late-year rebound and strong pipeline metrics—Massachusetts accounts for a large share of U.S. VC, the drug-development pipeline, and possess abundant lab space (63.2M sq ft with 31% vacancy) that could help fuel a rebound if capital returns to early-stage companies and policy supports competitiveness without unduly limiting China investments.













